Vistagen Therapeutics Inc (NASDAQ:VTGN) announced its quarterly earnings data on Monday. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.04.

Vistagen Therapeutics (NASDAQ:VTGN) opened at 3.80 on Tuesday. Vistagen Therapeutics has a one year low of $2.81 and a one year high of $10.25. The firm’s market cap is $30.29 million. The company has a 50 day moving average of $4.10 and a 200-day moving average of $4.00.

Separately, Zacks Investment Research upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a report on Friday, August 26th.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).

5 Day Chart for NASDAQ:VTGN

Receive News & Stock Ratings for Vistagen Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics Inc and related stocks with our FREE daily email newsletter.